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Abstract
Background: Women who have been treated for breast cancer may identify vasomotor symptoms, such as hot
flushes and night sweats (HFNS), as a serious problem. HFNS are unpleasant to experience and can have a significant
impact on daily life, potentially leading to reduced adherence to life saving adjuvant hormonal therapy. It is known
that Cognitive Behavioural Therapy (CBT) is effective for the alleviation of hot flushes in both well women and women
who have had breast cancer. Most women with breast cancer will see a breast care nurse and there is evidence that
nurses can be trained to deliver psychological treatments to a satisfactory level, whilst also maintaining treatment
fidelity. The research team will assess whether breast care nurses can effectively deliver a CBT intervention to alleviate
hot flushes in women with breast cancer.
Methods: This study is a multi-centre phase III individually randomised controlled trial of group CBT versus usual care
to reduce the impact of hot flushes in women with breast cancer. 120–160 women with primary breast cancer experiencing
seven or more problematic HFNS a week will be randomised to receive either treatment as usual (TAU) or participation in
the group CBT intervention plus TAU (CBT Group).
A process evaluation using May’s Normalisation Process Theory will be conducted, as well as practical and organisational
issues relating to the implementation of the intervention. Fidelity of implementation of the intervention will be conducted
by expert assessment. The cost effectiveness of the intervention will also be assessed.
Discussion: There is a need for studies that enable effective interventions to be implemented in practice. There is good
evidence that CBT is helpful for women with breast cancer who experience HFNS, yet it is not widely available. It is not yet
known whether the intervention can be effectively delivered by breast care nurses or implemented in practice. This study
will provide information on both whether the intervention can effectively help women with hot flushes and whether and
how it can be translated into routine clinical practice.
Trial registration: ISRCTN 12824632. Registered 25–01-2017.
Keywords: Breast cancer, Menopause, Hot flushes, Night sweats, CBT, Training, Nurses, Normalisation process theory
* Correspondence: D.R.Fenlon@swansea.ac.uk
1College of Human and Health Sciences, Swansea University, Swansea, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fenlon et al. BMC Women's Health  (2018) 18:63 
https://doi.org/10.1186/s12905-018-0550-z
Background
Hot flushes, also known as hot flashes, and night sweats
(HFNS) are experienced by up to 70% of women after treat-
ment for breast cancer [29]. HFNS are troublesome for
many women, having a significant impact on daily life and
sleep quality, with important social consequences affecting
employment, personal relationships and quality of life [17].
With natural menopause, HFNS gradually decrease in
number and intensity over the post-menopausal years.
With breast cancer, HFNS can be more extreme and per-
sistent: experienced by 34% of women more than five years
after diagnosis and by 50% of women more than five years
from menopause [16]. This is due in part to treatments for
breast cancer, which reduce or interfere with the action of
oestrogen in the body. Chemotherapy may precipitate an
early menopause [30] and tamoxifen and other hormonal
treatments cause or exacerbate HFNS [32]. Adjuvant hor-
mone therapies may be used sequentially for a minimum of
five years and now up to ten years post diagnosis. The
majority of women do not complete the recommended five
years of adjuvant hormone therapy, which may be partly
due to adverse side effects, such as HFNS, resulting in a
30% increased breast cancer mortality [25, 28].
The most effective treatment for HFNS is hormone
replacement therapy, which is contraindicated in ER+
breast cancer [31]. While there are other medications
available, such as selective serotonin re-uptake inhibitors
(SSRIs) and clonidine, they have unpleasant side effects,
and non-medical alternatives tend to lack efficacy [7]. Fur-
thermore, many women prefer not to take medication
after cancer, but instead favour self-management of meno-
pausal HFNS [34]. Surveys carried out by the National
Cancer Research Institute (NCRI) breast symptoms work-
ing party showed that there are no consistent standard
care pathways for people with HFNS and that very few
women are offered anything in the way of care or manage-
ment of this problem [15].
There is evidence that a structured cognitive behav-
ioural therapy (CBT), focusing on key elements of the ex-
perience of hot flushes and night sweats, delivered in
group format, is effective for the alleviation of HFNS in
both women with and without breast cancer [1, 12, 26]. In
line with the Medical Research Council’s guidance on de-
veloping and evaluating complex interventions [11] the
theoretical basis and the role of moderators and mediators
of the outcomes of CBT have been examined in previous
studies. Hunter and Mann [22] developed a theoretical
model of HFNS that draws upon symptom perception,
self-regulation and cognitive behavioural theories to ex-
plain women’s cognitive appraisal and behavioural reac-
tions to symptoms. The model was tested using structural
equation modelling [21] and an examination of mediators
in MENOS trials [10]. The results clearly suggest that
problem rating of HFNS (i.e. the impact of HFNS on daily
life) is mediated mainly by beliefs about HFNS, and that
changes in beliefs, as well as improvements in mood and
sleep, predict positive outcomes with CBT.
There may be a need to develop a variety of ways to
deliver the CBT intervention, but group sessions, led by
a health professional such as the breast care nurse
(BCN), provide a cost effective solution, and were posi-
tively viewed in the previous MENOS trial [2]. There are
also benefits with group CBT, such as improvements in
mood and quality of life, which have not been demon-
strated with self-help CBT [1]. Although CBT is known
to be effective, it is rarely offered within the NHS for
women with breast cancer. It is also not known whether
this intervention can be effectively delivered by BCNs in
the NHS context. Most women with breast cancer will
see a BCN and there is evidence to suggest that it is pos-
sible to train BCNs to deliver psychological interventions
to a satisfactory level and fidelity [24]. This study will
therefore test whether breast care nurses can be trained
to deliver CBT in an NHS context to effectively manage
HFNS in women who have had breast cancer.
A further consideration is that practical barriers can
prevent effective interventions from being delivered in
practice, so we will conduct a process evaluation, drawing
on May’s Normalisation Process Theory (NPT), [33], to
explore potential barriers to implementation. The theory
focuses on the dynamic processes that lead to innovations
being implemented and integrated into work on an every-
day basis. It is therefore a helpful way to assess what hap-
pens when multifaceted interventions are introduced into
practice. This includes what people’s actions are, collect-
ively and individually, and how and why the desired out-
comes are met (or not). The processes that take place
when people implement change are described by NPT as
coherence, cognitive participation, collective action and
reflexive monitoring. The intervention in this trial is an al-
ternative care pathway that includes CBT. The purpose of
the process evaluation is to understand the dynamics of
the care pathway and identify factors that are important
for embedding this intervention into practice. This evalu-
ation will focus on identifying and explaining the extent to
which the planned CBT is implemented into practice.
HFNS have been identified as a major physical symp-
tom by the breast cancer research gap analysis [13], re-
quiring research that identifies appropriate interventions
to enable women to manage this problem. The research
gap analysis also highlights an inadequate translation of
research findings into clinical practice and specifically
the need to consider how interventions such as CBT can
be better integrated to widen access.
Methods/Design
The study design is a randomised controlled trial (RCT),
with a formal process evaluation. The RCT will be a
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multi-centre phase III individually randomised controlled
trial of a BCN-delivered group CBT intervention versus
treatment as usual (TAU).
Study aims and objectives
The primary study aim is to evaluate the effectiveness of
group CBT delivered by breast care nurses on reducing
the impact of HFNS in women with breast cancer
26 weeks after randomisation.
Secondary aims include outcome and process issues.
These are to explore and evaluate:
1. The extent to which there is a reduction of the
impact of HFNS nine weeks after randomisation
in women with breast cancer
2. The extent to which there is a reduction of the
frequency of hot flushes and night sweats nine
and 26 weeks after randomisation in women with
breast cancer
3. The level of fidelity of the CBT when delivered by
breast care nurses
4. The effect of group CBT on quality of life and
other symptoms, e.g. sleep, anxiety
5. The effect on women’s hot flush beliefs and
behaviours
6. An estimate of the cost-effectiveness
7. The extent to which the planned CBT intervention
was implemented into practice, specifically:
 Exploring how and in what ways the therapy
was initially received, how individually and
collectively people practically conceptualised
and made sense of it (coherence)
 Assessing the degree of ownership of and
participation in the new practice by key
individuals (surgeons, managers, BCNs and
patients) and teams (cognitive participation)
 Identifying the individual and teamwork
carried out to sanction the new practice
(collective action)
 Exploring the perceived impact of the new
practice on staff work and on patient outcomes
(reflexive monitoring)
Study setting
Participants will be recruited from six NHS Hospital Trusts
in England and Wales. These centres will be selected from
those who express an interest through the NIHR Clinical
Research Network (CRN) and will have:
1. Availability of at least two BCNs willing to be
trained
2. Available room to deliver the CBT sessions
3. Written agreement to participate from the manager
Participants
120–160 women with primary breast cancer experiencing
seven or more problematic HFNS a week will be recruited
and randomised to the intervention or usual care.
Inclusion criteria are:
1. Women with primary breast cancer or ductal
carcinoma in situ (DCIS)
2. Women who have completed all primary treatment:
surgery and/or radiotherapy and/or chemotherapy
(may still be receiving adjuvant endocrine therapy
or Herceptin)
3. Aged 16 years or older
4. Experiencing seven or more HFNS/week with an
overall rating of 4/10 or above on the Hot Flush
Problem Rating Scale
5. Ability to attend group sessions
6. Signed informed consent
The exclusion criteria are:
1. Benign breast disease
2. Metastatic disease (our patient representatives
advised us that the group dynamics could be
dominated by issues of recurrence and disease
progression instead of focusing on HFNS if
people with metastatic disease were included)
3. Current use of other mind-body therapies to
help with HFNS, e.g. acupuncture, hypnosis
and mindfulness.
There will be no exclusion criterion relating to time
since diagnosis as long as participants have problematic
HFNS. Women who are taking medication or herbal
remedies for HFNS will be asked to continue with these
throughout the study.
Study processes
Due to the pragmatic nature of the study, and to emulate
the real world situation of this intervention, potential
participants will be identified and recruited as flexibly as
possible. Therefore, routes of identifying eligible women
will include identification from breast cancer follow up
clinics, phone clinics, leaflets and posters in clinics and
health and wellbeing events, by the research nurses, who
will check eligibility and take consent following GCP
guidelines.
Randomisation
Randomisation will be in cohort groups and stratified by
site. A computer-generated randomisation sequence will
be created by a statistician at the Clinical Trials Unit, allo-
cating participants in a one-to-one ratio, stratified by site
with fixed block size. This process will be repeated for
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each cohort group so that allocation does not affect the
allocation sequence of subsequent cohorts. Following
receipt of consent and completed baseline case report
forms (CRFs) from 12 to 16 eligible participants at a single
site participants will be randomised to either Group CBT
or TAU. The research nurse will be sent the allocation
results for all the women at one time point and they will
inform each participant of their group allocation (CBT or
TAU). Each site will aim to run two sequential groups of
the intervention of 6–8 women per group (NB. A possible
group of five (ten women recruited) was also possible via
TMG approval).
Intervention
Women in the intervention arm will attend weekly group
CBT sessions, lasting 90 min each, for six weeks. Sessions
will be delivered by BCNs who have been trained by a
clinical psychologist. The sessions will follow a structured
manual [20], which includes psycho-education and the
cognitive behavioural model; stress management; paced
breathing; cognitive and behavioural strategies to improve
wellbeing and for managing hot flushes; night sweats and
sleep; and maintaining changes.
Training
The BCNs involved in delivering the intervention will be
selected by sites and will be trained by a clinical psycholo-
gist to deliver the intervention. The nurses will be trained
as close as practically possible to delivery of the interven-
tion. Training will take place over two days, with 6 h of
training per day and an overnight stay in between. Know-
ledge and skills will be assessed throughout the training
using a variety of methods, including questionnaires and
role-plays. A telephone based top-up session will be con-
ducted immediately prior to the first group at each site
(within three weeks) in order to refresh the learning.
BCNs will use a manual [20] which contains detailed
session content, presentation slides and handouts, and
notes for facilitators. This will be sent to BCNs in advance
of the training days with tasks to complete in preparation,
including a sleep diary and relaxation CD. The training
will provide the background theoretical knowledge and
practical skills to facilitate group CBT for menopausal
symptoms by examining how thinking and behaviour can
have a significant impact on women’s experience of HFNS
following breast cancer treatment and helping women to
develop strategies to manage them. These include under-
standing negative emotions and HFNS, managing unhelp-
ful thoughts and behaviour, improving sleep and using
paced breathing to manage HFNS.
Supervision
BCNs will receive ongoing supervision of their delivery
of group CBT. They will be asked to write down their
reflections and any questions/problems after each ses-
sion they deliver and email it to the clinical psychologist
who trained them for supervision. Feedback on these
reflections will be made by email, telephone or Skype.
They can also refer back to the manual. Data will be
collected on the number and length of supervisory
sessions.
Adherence
Adherence to group CBT will be measured by the number
of sessions attended and the number of times that a
participant reports practising relaxation and paced breath-
ing each week. If participants do not attend a session, the
BCN will contact the participant by telephone to ascertain
the problem of attendance, and will discuss the appropri-
ate solution with the participant e.g. a telephone session.
Alternatively, the session is recorded as did not attend.
Telephone sessions will be kept to a minimum, and only
arranged if exceptional circumstances do not allow the
patient to attend the face-to-face session.
Fidelity
All group sessions will be audio recorded (with consent),
and 17% will be randomly selected (with a computer-
generated random number sequence), ensuring two ses-
sions per site are selected. An independent psychologist
(i.e. who has not been involved in BCN training), experi-
enced in CBT for HFNS, will rate them for adherence to
the treatment manual.
Treatment as usual arm
It is expected that TAU will be different at each site as
there is no current standard of care. Since randomisation
will be stratified by site this does not pose a problem. In
some centres, women will be given ad hoc advice about
HFNS, normally only if they raise the issue. Data collected
from a UK survey suggests that only 29% women were
asked if they were experiencing HFNS, only 2% were
referred to a menopause clinic and very few offered any
kind of relaxation or behavioural intervention [15].
In addition to standard NHS care, participants rando-
mised to the TAU arm will be offered a version of self-
help CBT following the 26-week assessment. This involves
giving women a booklet and CD that includes the same
information as group CBT sessions, as well as a one-to-
one face-to-face meeting with a trained BCN to discuss
the key elements of the booklet. This will be followed up
by two telephone calls to discuss progress, encourage use
of the booklet and homework and to address any prob-
lems. Offering self-help CBT will be used as a strategy to
increase adherence to the study.
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Outcome measures
Outcome measures will be completed at baseline, week
nine and week 26. Baseline demographic and clinical
information, including use of current therapies, will be
collected and input on the database. A team from the
Clinical Informatics Research Unit at the University of
Southampton will develop the trial database. The infra-
structure will be provided by ALEA.
Hot flushes and night sweats assessment
The primary study outcome will be measured using the
Hot Flushes and Night Sweats (HFNS) Problem Rating
Scale [18]. This measures the extent to which hot flushes
and night sweats are problematic, distressing and interfere
with daily life. Three items are rated on a 10-point scale –
higher scores are indicative of greater bother/impact on
daily life. A change of 2 points on this scale is considered
clinically relevant [1, 26]. This scale also assesses HFNS
frequency asking women to estimate how many HFNS they
have had in the past week. A three day diary will be col-
lected at baseline to validate the accuracy of the estimate.
The Short Form Hot Flush Beliefs and Behaviours
Scale (HFBBS) is a 16-item scale that includes items
about beliefs and behaviours about hot flushes [19].
Subscales include: (i) beliefs about HF in social context
(e.g. everyone is looking at me), (ii) beliefs about coping/
control of hot flushes (e.g. when I have a HF I think they
will never end), and (iii) beliefs about night sweats and
sleep (e.g. if I have NS I’ll never get back to sleep). HFNS
Behaviours include (i) positive coping behaviour, e.g.
accepting HFNS, using breathing and calming responses;
(ii) avoidance behaviour.
The Hot Flash Related Daily Interference Scale
(HFRDIS) [9] measures the impact of hot flushes on a
variety of domains including work, social, and leisure
activities on a scale from 0 to 10.
Quality of life
QoL will be assessed using the EQ-5D-5 L and the FACT-
B [4]. FACT -B is a widely used and well-validated 37-item
questionnaire designed for use in breast cancer. Five sub-
scales assess physical, social, emotional and functional
well-being, as well as concerns specific to women with
breast cancer. The endocrine subscale (ES) [14] includes
19 items related to hormone treatment.
Anxiety and depression
The Generalised Anxiety Disorder Questionnaire (GAD-
7) is a self-administered patient questionnaire consisting
of seven items (e.g. feeling nervous, restlessness) used as
a severity measure for generalised anxiety disorder [35].
The Patient Health Questionnaire-9 (PHQ-9) is a meas-
ure of depressive mood. It is used to examine the severity
of depression and response to treatment. It is self-
administered and patients are asked how often they have
been bothered by nine problems (e.g. trouble concentrat-
ing and poor appetite) over the previous two weeks [23].
Sleep
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated
questionnaire that assesses sleep quality and distur-
bances from 19 individual items, including sleep quality,
sleep latency, sleep duration, habitual sleep efficiency,
sleep disturbance, sleep medication use and daytime dys-
function (Bussye et al. [6]). These are analysed in seven
component scores with the sum of scores yielding one
total score. This has been validated for use in women
with breast cancer [8].
Health economics assessment
The economic analysis will estimate the costs of providing
the CBT intervention, and the cost consequences of the
intervention for NHS services and for costs borne by pa-
tients. However, an economic evaluation will be conducted
only if the intervention proves to be effective, as defined by
a two-point improvement in the HFNS. The cost of the
intervention will be reported regardless of its effectiveness.
If effective, cost effectiveness will be expressed in cost per
unit change in HFNS and per QALY, based on the incre-
mental differences between arms. The identification and
collection of costs will be undertaken using the following
methods:
1) NHS
Data on the use of medication, primary care visits, and
out-patient visits will be collected using a resource use
questionnaire. The cost of the intervention will be based
on nurse logs to record staff training cost, and time to
deliver the intervention. This information will be used
for sensitivity analysis from a societal perspective. We
will use an adapted form of the client service receipt
inventory (CSRI), Beecham & Knapp, [3].
2) Women
We will estimate out-of-pocket spending such as herbal
remedies, acupuncture or alternative therapies and time
off work due to hot flushes. Collection of such informa-
tion from each participant will be through a resource use
questionnaire at 9 and 26 weeks. QoL will be measured by
EQ-5D-5 L and will be collected at baseline, 3, 6, 9 and
26 weeks.
Process evaluation
An evaluation questionnaire will be administered to
those participants in the Group CBT intervention arm
at the end of the six-week intervention. Interviews will
be conducted with patients and key stakeholders from
each of the study centres at the completion of the
intervention. Semi-structured interview schedules will be
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developed, guided by consideration of the four areas
identified through NPT [33], which includes an explor-
ation of barriers to implementation and how they were
tackled. Key stakeholders will include all the participat-
ing BCNs and 1 key manager and 1 key member of clin-
ical staff at each site identified by the BCNs. Interviews
will be conducted with BCNs prior to, and after delivery
of the intervention. All other stakeholders will be inter-
viewed after the intervention. Interviews will be either
face-to-face or by telephone.
Analysis
Sample size calculation
A difference of two points or more in the HFNS Problem
Rating Scale is regarded as clinically relevant. In order to
detect a two-point difference (standard deviation 2.4; stan-
dardised effect size 0.8, [26] in mean HFNS problem
rating for the comparison of CBT to TAU, 90% power
would require 64 participants in total (32 per randomised
arm), assuming 2-sided significance level of 0.05. Allowing
for an inflation factor of 1.49 (intraclass correlation of 0.07
with 8 participants per group, (Wampold and Brown [36])
to adjust for expected clustering of outcomes within
groups, gives a minimum sample size of 96, which in-
creases to 120 allowing for 20% loss to follow-up. A sam-
ple size of 120 will also allow each site to run two groups
to ensure that a comprehensive process evaluation can be
conducted. If each site recruits the minimum number of
six people per group, then 120 participants in total will be
achieved. If they recruit the maximum of eight per group
(allowing up to 160 participants in total) this will provide
greater power for the analyses of secondary outcomes.
Primary and secondary analyses
Scales from the validated questionnaire measures will be
calculated according to published scoring algorithms. The
difference in the HFNS Problem Rating Scale (primary out-
come) between the two randomised groups will be tested
using a linear mixed model, utilising fixed and random
effects. The regression model will compare the HFNS prob-
lem rating subscale between intervention groups at follow-
up, adjusting for baseline HFNS problem rating score and
stratification factor (site). Greater precision of estimates is
expected within therapy groups (clustering effect) so
models will also be adjusted for the group. Secondary out-
comes at post-treatment will be analysed in a similar way.
Follow-up data at subsequent time intervals will also be ex-
plored through linear mixed models utilising repeated mea-
sures analyses, allowing simultaneous modelling of the
three outcome time points. Analyses will be based on a
modified intention-to-treat sample (i.e. excluding partici-
pants who contribute fewer than two items on the primary
outcome measure). Per protocol analysis for those compli-
ant will be performed as a sensitivity analysis.
Health economics analysis
All relevant resource items identified will be costed using
published national cost data (British National Formulary
and Personal Social Services Research Unit, and NHS ref-
erence cost). Accumulated costs and quality adjusted life
years (QALYs) per patient will be estimated by means of
area under the curve. Where appropriate we will estimate
incremental cost-effectiveness ratios. We will estimate
mean values and 95% percentiles using non-parametric
bootstrapping. We will produce cost-effectiveness accept-
ability curves to illustrate the uncertainty of such
estimates. Major assumptions made in the costing and
QALYs will be tested by means of sensitivity analyses.
Qualitative analysis of process evaluation
Interview recordings will be transcribed and all identifying
data will be anonymised. The data will be analysed using
thematic analysis [5] and the principles of open coding,
constant comparison, negative case analysis, and memo
writing [27]. In addition, some a-priori codes derived from
the literature review will be used. The NVivo 10 software
program will be used to facilitate data storage, categorisa-
tion and retrieval. Members of the research team will code
the interviews, hold coding meetings, and revise the
coding strategy. After coding, themes will be proposed
and tested in the data. Analysis meetings with the research
team will involve refining the themes.
Fidelity of delivery of the therapy will be assessed from
randomly selected audio recordings. An experienced,
independent clinical psychologist will indicate on coding
sheets the extent to which the group leader covered each
topic, using the Quality Assurance for Group CBT inter-
vention Independent Sessional Assessment tool used in
MENOS study 1 [26]. Coding sheets include specific com-
ponents of the intervention (e.g. reviewing homework,
providing information about the role of stress, demon-
strating paced breathing in the session, group discussion
of behaviours relating to HFNS) developed for the trial.
Discussion
There is a need for studies that enable effective interven-
tions to be implemented in practice. There is good evidence
that CBT is helpful for women with breast cancer [26], yet
it is not widely available. It is not yet known whether the
intervention can be effectively delivered by BCNs. This
study will provide information on both whether the inter-
vention can effectively help women with HFNS and
whether and how it can be translated into routine clinical
practice.
Despite the fact that CBT has been demonstrated to be
effective in relieving the bother of HFNS in women who
have had breast cancer, it is not widely available and is
rarely offered to women who are suffering these symp-
toms. One reason for this could be the relatively small
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Fig. 1 Schedule of observations and procedures
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number of therapists available to offer this kind of inter-
vention. Most women with breast cancer have access to a
BCN and nurses can be effectively trained to deliver
psychological interventions. If it can be shown that this
intervention can be successfully delivered by BCNs this
could make the intervention available more widely. How-
ever, there are often other barriers to the implementation
of effective therapies, so this study will provide a qualita-
tive evaluation of challenges and barriers and how partici-
pating centres overcame these to implement this service
into their practice (Figs. 1, 2 and Additional file 1).
End of the trial
The end of trial is defined as when the last patient has
had their last data collected.
Trial status
This clinical trial was registered in January 2017 (ISRCTN
(12824632)). Recruitment opened in January 2017 and is
expected to be completed by March 2018. The current
protocol is version 3, dated 21-April-2017. Results will be
published at the end of the trial in a peer reviewed journal
(authored by the members of the TMG), presented at
Fig. 2 Study Schema
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international conferences, end of trial summaries will
appear on the relevant databases and results fed back to
recruiting sites so that any participants are able to access
the results via their treating clinician.
Oversight groups and committees
The trial is overseen by the TSC. No DMEC will be con-
vened; this role will be assumed by the TSC.
Additional file
Additional file 1: Model Consent Form. (PDF 111 kb)
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